Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen

被引:5
|
作者
Soltani Hekmat, Ava [1 ]
Javanmardi, Kazem [1 ]
机构
[1] Fasa Univ Med Sci, Dept Physiol, Fasa, Iran
关键词
ACTIVATED PROTEIN-C; FACTOR-V; PLATELET; GENDER; CYCLE; AGE;
D O I
10.1155/2021/7702863
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
People who receive the ChAdOx1 nCoV-19 vaccine, particularly perimenopausal women who are on birth control or postmenopausal women who take estrogen supplements, may experience thrombosis and thrombocytopenia. Estrogen and the ChAdOx1 nCoV-19 vaccine both have the potential to cause thrombus in different ways. Some postmenopausal women who are also taking estrogens may develop thrombosis and thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine. Therefore, women are encouraged to stop taking drugs containing estrogen before receiving this vaccine. Furthermore, consuming fish oil can help reduce the risk of developing blood clots among women who are in the luteal phase and, thus, have high estrogen levels. In addition, ChAdOx1 nCoV-19's side effects in young women could be mitigated by administering it during the follicular phase.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] A case of myopericarditis with pleuritis following AstraZeneca Covid-19 vaccination
    Hung, Y. P.
    Sun, K. S.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2021, 114 (12) : 879 - 881
  • [42] The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis
    Jain, Vageesh
    Lorgelly, Paula
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2022, : 648 - 654
  • [43] Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female
    Majid, Imran
    Mearaj, Samia
    DERMATOLOGIC THERAPY, 2021, 34 (06)
  • [44] Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
    Wise, Jacqui
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 372 : n699
  • [45] Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster
    Hung, Ivan F. N.
    Poland, Gregory A.
    LANCET, 2021, 397 (10277): : 854 - 855
  • [46] Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia
    Garnier, Matthieu
    Curado, Adelya
    Billoir, Paul
    Barbay, Virginie
    Demeyere, Matthieu
    Dacher, Jean-Nicolas
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2021, 102 (10) : 649 - 650
  • [47] ABO blood group associated with cerebral venous thrombosis after Oxford-AstraZeneca COVID-19 vaccination: a case-control study
    Ken-Dror, Gie
    Sharma, Pankaj
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2024, 117 (02) : 69 - 76
  • [49] COVID-19 in Kidney Transplant Recipients Vaccinated With Oxford-AstraZeneca COVID-19 Vaccine (Covishield): A Single-center Experience From India
    Meshram, Hari Shankar
    Kute, Vivek B.
    Shah, Nauka
    Chauhan, Sanshriti
    Navadiya, Vijay V.
    Patel, Ansy H.
    Patel, Himanshu V.
    Engineer, Divyesh
    Banerjee, Subho
    Rizvi, Jamal
    Mishra, Vineet V.
    TRANSPLANTATION, 2021, 105 (09) : E100 - E103
  • [50] Risk of adverse events following CoronaVac's COVID-19 vaccination in women with and without autoimmunity
    Sumantri, Stevent
    Haryanto, Maria Aurelia
    Widyastuti, Euphemia Seto Anggraini
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2023, 20